A Phase 2/3 interventional study of ALK-001 oral capsule and Placebo oral capsule in Geographic Atrophy, Age Related Macular Degeneration and AMD, sponsored by Alkeus Pharmaceuticals, Inc.. Completed at 24 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2025-11-03.
Sponsored by Alkeus Pharmaceuticals, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.
Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 40th largest by enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2019, is one of 5 in phase 2/3, and was the 59th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
University of Utah · Sites in United States
Ages 65–90
Cellio Therapeutics Inc · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 65 · Phase 3 20
First in 2000; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 200 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 98 across the 107 interventional studies, 138 across the 24 observational. Of the 79 that completed or were terminated, 40 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 131 have an industry lead sponsor. The 10 most frequent:
Alkeus Pharmaceuticals, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Alkeus Pharmaceuticals, Inc. has 1 study filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
12 of the studies in Geographic Atrophy with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT06769048Boehringer IngelheimA Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | 2026-12-22 |
| NCT07747662University of Wisconsin, MadisonAdaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study | 2027-02 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 131 studies in Geographic Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD).
Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.
There is no oral treatment available for Geographic Atrophy secondary to AMD. AMD is characterized by an age-related degeneration of the retina.
The root cause for this degeneration or why some people develop AMD while others do not, is unknown. Over 20 years ago, it was hypothesized that the dimerization of vitamin A may be a significant contributor to the etiology of AMD. The eye indeed uses vitamin A as a cofactor to sense light, and a striking chemical signature of the aging and degenerating retina is the accumulation of vitamin A dimers in the retinal pigment epithelium (RPE) and the underlying Bruch's membrane. In rodent models, high levels of vitamin A dimers correlate with poor retinal health, and a variety of mechanisms have been proposed by which vitamin A dimers may induce retinal toxicity. It has been argued that these mechanisms participate in the development and progression of AMD.
ALK-001, the study drug, is a modified form of vitamin A. When taken once a day as a capsule, it replaces natural vitamin A in the body with one that forms vitamin A dimers more slowly. This study will measure the extent to which treatment with ALK-001 slows the progression of Geographic Atrophy.
Major Inclusion Criteria:
- At least one eye with geographic atrophy secondary to dry age-related macular degeneration (AMD)
Major Exclusion Criteria:
- Medical condition, which may interfere with the progression of GA, prevent performance of study procedures, compliance with protocol, or continuous participation in the study
Capsule
Drug: ALK-001 oral capsule
Capsule
Drug: Placebo oral capsule
Daily administration for 24 months
Also known as: C20-D3-Retinyl Acetate, C20 Deuterated vitamin A
Daily administration for 24 months
Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF)
Time frame: Baseline to 24 months
Number of Participants With Adverse Events
Time frame: Baseline to 24 months
Changes in Visual Acuity
Changes in LLVA and BCVA
Time frame: Baseline to 24 months
| Milestone | ALK-001 | Placebo |
|---|---|---|
| Started | 135 | 63 |
| Completed | 94 | 43 |
| Not completed | 41 | 20 |
| mm2/year | ALK-001 | Placebo |
|---|---|---|
| Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF) | 1.62 ± 0.081 | 1.87 ± 0.116 |
| Participants | ALK-001 | Placebo |
|---|---|---|
| Number of Participants With Adverse Events | 97 | 52 |
Changes in LLVA and BCVA
| letters | ALK-001 | Placebo |
|---|---|---|
| LLVA | -3.896 ± 1.316 | -8.298 ± 1.835 |
| BCVA | -6.862 ± 1.251 | -10.161 ± 1.771 |
Collected over Two years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ALK-001 | 5/135 (3.7%) | 26/135 (19.3%) | 59/135 (43.7%) |
| Placebo | 1/63 (1.6%) | 14/63 (22.2%) | 34/63 (54%) |
| Event | ALK-001 | Placebo |
|---|---|---|
| Corona virus infectionInfections and infestations | 0/135 | 3/63 |
| Cerebrovascular accidentNervous system disorders | 5/135 | 1/63 |
| Hip fractureInjury, poisoning and procedural complications | 0/135 | 2/63 |
| PneumoniaInfections and infestations | 3/135 | 0/63 |
| DeathGeneral disorders | 3/135 | 1/63 |
| SyncopeNervous system disorders | 0/135 | 1/63 |
| Supraventricular extrasystolesCardiac disorders | 0/135 | 1/63 |
| InfectionInfections and infestations | 0/135 | 1/63 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/135 | 1/63 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/135 | 1/63 |
| Event | ALK-001 | Placebo |
|---|---|---|
| Blood triglycerides increasedInvestigations | 15/135 | 5/63 |
| Corona virus infectionInfections and infestations | 7/135 | 6/63 |
| FallInjury, poisoning and procedural complications | 9/135 | 6/63 |
| Blood alkaline phosphatase increasedInvestigations | 10/135 | 5/63 |
| Urinary tract infectionInfections and infestations | 5/135 | 5/63 |
| Glomerular filtration rate decreasedInvestigations | 6/135 | 4/63 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/135 | 3/63 |
| Age, Categorical(Participants) | ALK-001 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 3 | 8 |
| >=65 years | 130 | 60 | 190 |
| Sex: Female, Male(Participants) | ALK-001 | Placebo | Total |
|---|---|---|---|
| Female | 91 | 45 | 136 |
| Male | 44 | 18 | 62 |
| Ethnicity (NIH/OMB)(Participants) | ALK-001 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 4 | 6 |
| Not Hispanic or Latino | 133 | 59 | 192 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | ALK-001 | Placebo | Total |
|---|---|---|---|
| United States | 135 | 63 | 198 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2019 to primary completion in Jul 2023, 50 months.
Results were first posted in Oct 2025, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gildeuretinol acetate
Alkeus Pharmaceuticals, Inc.